Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017
Abstract Background Plasmodium vivax is the predominant Plasmodium species in Afghanistan. National guidelines recommend the combination of chloroquine and primaquine (CQ-PQ) for radical treatment of P. vivax malaria. Artesunate in combination with the antifolates sulfadoxine-pyrimethamine (SP) has...
Main Authors: | Kasama Rakmark, Ghulam R. Awab, Jureeporn Duanguppama, Usa Boonyuen, Arjen M. Dondorp, Mallika Imwong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Malaria Journal |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12936-020-03319-0 |
Similar Items
-
Monitoring the efficacy of antimalarial medicines in India via sentinel sites: Outcomes and risk factors for treatment failure
by: Neelima Mishra, et al.
Published: (2016-01-01) -
Change in mutation patterns of Plasmodium vivax dihydrofolate reductase (Pvdhfr) and dihydropteroate synthase (Pvdhps) in P. vivax isolates from malaria endemic areas of Thailand
by: Jiraporn Kuesap, et al.
Published: (2011-08-01) -
Type 2 antifolates in the chemotherapy of falciparum malaria
by: Delfino Reinaldo T., et al.
Published: (2002-01-01) -
Polymorphism of Antifolate Drug Resistance in Plasmodium vivax From Local Residents and Migrant Workers Returned From the China-Myanmar Border
by: Weilin Zeng, et al.
Published: (2021-06-01) -
Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017
by: Rakmark, K, et al.
Published: (2020)